Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats

FEBS Journal

Volumn 278, Issue 22, 2011, Pages 4425-4434

  Braidy, Nady ^a   Guillemin, Gilles J ^a,b   Mansour, Hussein ^c   Chan Ling, Tailoi ^c   Grant, Ross ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b St Vincent's Centre for Applied Medical Research   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d SYDNEY ADVENTIST HOSPITAL   (Australia)

Author keywords

aging; indoleamine 2,3 dioxygenase (IDO); kynurenine pathway; NAD +; tryptophan

Indexed keywords

ALPHA AMINO ACID; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; KYNURENINE ACID; NICOTINATE NUCLEOTIDE PYROPHOSPHORYLASE (CARBOXYLATING); PICOLINIC ACID; QUINOLINIC ACID; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG;

AGED; AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BRAIN METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME METABOLISM; FEMALE; KIDNEY METABOLISM; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

AGING; ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY; KYNURENINE; LIVER; PENTOSYLTRANSFERASES; PICOLINIC ACIDS; QUINOLINIC ACID; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TRANSAMINASES; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

RATTUS; RATTUS NORVEGICUS;

EID: 80155201282     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08366.x     Document Type: Article

References (69)

1. Beal MF, Ferrante RJ, Swartz KJ, &, Kowall NW, (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 11, 1649-1659.
2. Guillemin GJ, Brew BJ, Noonan CE, Knight TG, Smythe GA, &, Cullen KM, (2007) Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques. In International Congress Series (, Takai K, ed) pp. 404-408.Elsevier, NY.
3. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, &, Cullen KM, (2005) Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 31, 395-404. (Pubitemid 41059860)
4. Guillemin GJ, Kerr SJ, &, Brew BJ, (2005) Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res 7, 103-123.
5. Guillemin GJ, &, Brew BJ, (2007) Chronic HIV infection leads to an Alzheimer's disease like illness. Involvement of the kynurenine pathway. In International Congress Series (, Takai K, ed.), pp. 324-334.Elsevier, NY.
6. Magni G, Amici A, Emanuelli M, Raffaelli N, &, Ruggieri S, (1999) Enzymology of NAD+ synthesis. Adv Enzymol Relat Areas Mol Biol 73, 135-182, xi.
7. Ying W, (2006) NAD+ and NADH in cellular functions and cell death. Front Biosci 11, 3129-3148. (Pubitemid 43800402)
8. Ying W, (2007) NAD+ and NADH in brain functions, brain diseases and brain aging. Front Biosci 12, 1863-1888. (Pubitemid 46846813)
9. Berger F, Ramirez-Hernandez MH, &, Ziegler M, (2004) The new life of a centenarian: signalling functions of NAD(P). Trends Biochem Sci 29, 111-118. (Pubitemid 38314856)
10. Blagosklonny MV, (2007) An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today 12, 218-224.
11. Burkle A, (2005) Poly(ADP-ribose). The most elaborate metabolite of NAD+. FEBS J 272, 4576-4589. (Pubitemid 41372054)
12. Burkle A, Beneke S, &, Muiras ML, (2004) Poly(ADP-ribosyl)ation and aging. Exp Gerontol 39, 1599-1601. (Pubitemid 39576131)
13. Mackay GM, Forrest CM, Stoy N, Christofides J, Egerton M, Stone TW, &, Darlington LG, (2006) Tryptophan metabolism and oxidative stress in patients with chronic brain injury. Eur J Neurol 13, 30-42.
14. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, &, Lowry CA, (2006) Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med 8, 1-27. (Pubitemid 44322753)
15. Burke F, Knowles RG, East N, &, Balkwill FR, (1995) The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int J Cancer 60, 115-122.
16. Fujigaki S, Saito K, Sekikawa K, Tone S, Takikawa O, Fujii H, Wada H, Noma A, &, Seishima M, (2001) Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 31, 2313-2318. (Pubitemid 32785349)
17. Guillemin GJ, Smith DG, Williams K, Smythe GA, Dormont D, &, Brew BJ, (2001) β amyloid peptide 1-42 induces human macrophages to produce the neurotoxin quinolinic acid. J Neuroimmunol 118, 112.
18. Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, &, Shearer GM, (2006) HIV-1 inhibits CD4+ T cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109, 3351-3359.
19. Frumento G, Piazza T, Di Carlo E, &, Ferrini S, (2006) Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 6, 233-237.
20. Grant RS, Naif H, Thuruthyil SJ, Nasr N, Littlejohn T, Takikawa O, &, Kapoor V, (2000) Induction of indolamine 2,3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent. J Virol 74, 4110-4115. (Pubitemid 30214416)
21. De Castro F, Price J, &, Brown R, (1956) Reduced triphophopyridine- nucleotide requirement for the enzymatic formation of 3-hydroxykynurenine from L-kynurenine. J Am Chem Soc 78, 2904-2905.
22. Boeck CR, Ganzella M, Lottermann A, &, Vendite D, (2004) NMDA preconditioning protects against seizures and hippocampal neurotoxicity induced by quinolinic acid in mice. Epilepsia 45, 745-750. (Pubitemid 38890971)
23. Bari F, Nagy K, Guidetti P, Schwarcz R, Busija DW, &, Domoki F, (2006) Kynurenic acid attenuates NMDA-induced pial arteriolar dilation in newborn pigs. Brain Res 1069, 39-46. (Pubitemid 43145896)
24. Beal MF, Swartz K, &, Isacson O, (1992) Developmental changes in brain kynurenic acid concentrations. Dev Brain Res 68, 136-139.
25. Stone TW, &, Connick JH, (1985) Quinolinic acid and other kynurenines in the central nervous system. Neuroscience 15, 597-617. (Pubitemid 15236335)
26. Stone TW, &, Darlington LG, (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1, 609-620. (Pubitemid 37361524)
27. Guillemin GJ, &, Brew BJ, (2002) Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep 7, 199-206.
28. Guillemin GJ, Wang L, &, Brew BJ, (2005) Quinolinic acid selectively induces apoptosis of human astocytes: potential role in AIDS dementia complex. J Neuroinflammation 2, 16.
29. Braidy N, Grant R, Brew BJ, Adams S, Jayasena T, &, Guillemin GJ, (2009) Effects of Kynurenine pathway metabolites on intracellular NAD+ synthesis and cell death in human primary astrocytes and neurons. IJTR 2, 61-69.
30. Braidy N, Grant R, Adams S, Brew BJ, &, Guillemin G, (2009) Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 16, 77-86.
31. Patneau D, &, Mayer M, (1990) Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors. J Neurosci 10, 2385-2399.
32. Beninger RJ, Colton AM, Ingles JL, Jhamandas K, &, Boegman RJ, (1994) Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. Neuroscience 61, 603-612. (Pubitemid 24240308)
33. Coleman P, (1989) How old is old? Neurobiol Aging 10, 115.
34. Comai S, Costa CV, Ragazzi E, Bertazzo A, &, Allegri G, (2005) The effect of age on the enzyme activities of tryptophan metabolism along the kynurenine pathway in rats. Clin Chim Acta 360, 67-80. (Pubitemid 41225395)
35. Crepaldi G, Allegri G, De Antoni A, Costa C, &, Muggeo M, (1975) Relationship between tryptophan metabolism and vitamin B6 and nicotinamide in aged subjects. Acta Vitaminol Enzymol 29, 140-144.
36. Oxenkrug G, (2010) The extended life span of Drosophila melanogaster eye color (white and vermilion) mutants with impaired formation of kynurenine. J Neural Transm 117, 23-26.
37. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, &, Fuchs D, (2004) Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 37, 684-687. (Pubitemid 39078460)
38. Owens MJ, &, Nemeroff CB, (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40, 288-295. (Pubitemid 24072594)
39. Fuchs D, Werner E, Dierich M, &, Wachter H, (1988) Cellular immune activation in the brain and human immunodeficiency virus infection. Ann Neurol 24, 289.
40. Baran H, Jellinger K, &, Deecke L, (1999) Kynurenine metabolism in Alzheimer's disease. J Neural Transm 106, 165-181. (Pubitemid 29137514)
41. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, &, Fuchs D, (2000) Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 107, 343-353. (Pubitemid 30162696)
42. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, &, Fuchs D, (1999) Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 467, 133-138. (Pubitemid 32202153)
43. Moroni F, Lombardi G, Moneti G, &, Aldinio C, (1984) The excitotoxin quinolinic acid is present in the brain of several mammals and its cortical content increases during the aging process. Neurosci Lett 47, 51-55. (Pubitemid 14111333)
44. Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, &, Kalina P, (2005) Age-related increase of kynurenic acid in human cerebrospinal fluid-IgG and beta2-microglobulin changes. Neurosignals 14, 126-135. (Pubitemid 41160299)
45. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A, et al. (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115, 1249-1273.
46. Hartai Z, Juhasz A, Rimanoczy A, Janaky T, Donko T, Dux L, Penke B, Toth GK, Janka Z, &, Kalman J, (2007) Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int 50, 308-313. (Pubitemid 46097159)
47. Guillemin GJ, Smith DG, Williams K, Smythe GA, Dormont D, &, Brew BJ, (2001) Beta-Amyloid peptide 1-42 induces human macrophages to produce the neurotoxin quinolinic acid. J Neuroimmunol 118, 336.
48. Rahman A, Ting K, Cullen KM, Brew BJ, Braidy N, &, Guillemin GJ, (2009) The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS ONE 4, e6344.
49. Gramsbergen JB, Schmidt W, Turski WA, &, Schwarcz R, (1992) Age-related changes in kynurenic acid production in rat brain. Brain Res 588, 1-5.
50. Leung J, Marphis T, Craver RD, &, Silverstein DM, (2004) Altered NMDA receptor expression in renal toxicity: protection with a receptor antagonist. Kidney Int 66, 167-176. (Pubitemid 38870092)
51. Khan JA, Forouhar F, Tao X, &, Tong L, (2007) Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets 11, 695-705. (Pubitemid 46730083)
52. Kiefmann R, Heckel K, Doerger M, Schenkat S, Kupatt C, Stoeckelhuber M, Wesierska-Gadek J, &, Goetz A, (2004) Role of PARP on iNOS pathway during endotoxin-induced acute lung injury. Intensive Care Med 30, 1421-1431. (Pubitemid 38951727)
53. Kolthur-Seetharam U, Dantzer F, McBurney M, de Murcia G, &, Sassone-Corsi P, (2006) Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP1 in response to DNA damage. Cell Cycle 5, 873-877. (Pubitemid 44145583)
54. Lin H, (2007) Nicotinamide adenine dinucleotide: beyond a redox coenzyme. Org Biomol Chem 5, 2541-2554. (Pubitemid 47192304)
55. Baur JA, &, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5, 493-506. (Pubitemid 44136961)
56. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, &, Sinclair DA, (2002) Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277, 45099-45107. (Pubitemid 36159111)
57. Hansson E, Muyderman H, Leonova J, Allansson L, Sinclair J, Blomstrand F, Thorlin T, Nilsson M, &, Ronnback L, (2000) Astroglia and glutamate in physiology and pathology: aspects on glutamate transport, glutamate-induced cell swelling and gap-junction communication. Neurochem Int 37, 317-329. (Pubitemid 30254164)
58. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang L, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196. (Pubitemid 37150899)
59. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, et al. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26, 3169-3179. (Pubitemid 47057498)
60. Lamming DW, Wood JG, &, Sinclair DA, (2004) Small molecules that regulate lifespan: evidence for xenohormesis. Mol Microbiol 53, 1003-1009. (Pubitemid 39120424)
61. Pearson K, Baur J, Lewis K, Peshkin L, Price N, Labinskyy N, Swindell W, Kamara D, Minor R, Perez E, et al. (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending lifespan. Cell Metab 8, 157-168.
62. Sinclair D, (2005) Toward a unified theory of calorie restriction and longevity regulation. Mech Ageing Dev 126, 987-1002. (Pubitemid 41033180)
63. Collier TJ, &, Coleman PD, (1991) Divergence of biological and chronological aging: evidence from rodent studies. Neurobiol Aging 12, 685-693.
64. Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, &, Brew BJ, (2007) Characterization of the kynurenine pathway in human neurons. J Neurosci 27, 12884-12892. (Pubitemid 350161746)
65. Smythe GA, Braga O, Brew BJ, Grant RS, Guillemin GJ, Kerr SJ, &, Walker DW, (2002) Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. Anal Biochem 301, 21-26. (Pubitemid 34113674)
66. Kapoor V, Kapoor R, &, Chalmers J, (1994) Kynurenic acid, an endogenous glutamate antagonist, in SHR and WKY rats: possible role in central blood pressure regulation. Clin Exp Pharmacol Physiol 21, 891-896.
67. Heyes MP, &, Quearry BJ, (1988) Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection. J Chromatogr 428, 340-344.
68. Takikawa O, Yoshida R, Kido R, &, Hayaishi O, (1986) Tryptophan degredation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem 261, 3648-3653. (Pubitemid 17200663)
69. Feigelson P, &, Greengard O, (1961) A microsomal iron-porphyrin activator of rat liver tryptophan pyrrolase. J Biol Chem 236, 153-157.